메뉴 건너뛰기




Volumn 22, Issue 6, 2009, Pages 686-697

Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; LOSARTAN; NIFEDIPINE; PERINDOPRIL; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

EID: 70849096295     PISSN: 15572625     EISSN: 15587118     Source Type: Journal    
DOI: 10.3122/jabfm.2009.06.090094     Document Type: Article
Times cited : (24)

References (61)
  • 1
    • 0041732327 scopus 로고    scopus 로고
    • New evidence on the importance of the renin-angiotensin system in the treatment of higher-risk patients with hypertension
    • DOI 10.1097/00004872-200309000-00001
    • Sleight P, Yusuf S. New evidence on the importance of the rennin-angiotensin system in the treatment of higher-risk patients with hypertension. J Hypertens 2003;21:1599-1608 (Pubitemid 37076335)
    • (2003) Journal of Hypertension , vol.21 , Issue.9 , pp. 1599-1608
    • Sleight, P.1    Yusuf, S.2
  • 2
    • 36749043046 scopus 로고    scopus 로고
    • Effects of rennin-angiotensin system inhibition on end-organ protection: Can we do better?
    • Weir MR. Effects of rennin-angiotensin system inhibition on end-organ protection: can we do better? Clin Ther 2007;29:1803-1824
    • (2007) Clin Ther , vol.29 , pp. 1803-1824
    • Weir, M.R.1
  • 3
    • 34248362697 scopus 로고    scopus 로고
    • Role of renin angiotensin system inhibitors in cardiovascular and renal protection: A lesson from clinical trials
    • DOI 10.2174/138161207780618768
    • Stojiljkovic L, Behnia R. Role of rennin angiotensin system inhibitors in cardiovascular and renal protection: a lesson from clinical trials. Curr Pharm Des 2007;13:1335-1445 (Pubitemid 46746371)
    • (2007) Current Pharmaceutical Design , vol.13 , Issue.13 , pp. 1335-1345
    • Stojiljkovic, L.1    Behnia, R.2
  • 4
    • 33645860811 scopus 로고    scopus 로고
    • Feasibility of treating prehypertension with an angiotensin-receptor blocker
    • Julius S, Nesbitt SD, Egan BM, et al. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med 2006;354:1685-1697
    • (2006) N Engl J Med , vol.354 , pp. 1685-1697
    • Julius, S.1    Nesbitt, S.D.2    Egan, B.M.3
  • 5
    • 45149131667 scopus 로고    scopus 로고
    • Effects of intensive glucose lowering in type 2 diabetes
    • The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group
    • The Action to Control Cardiovascular Risk in Diabetes (ACCORD) study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358: 2545-2559
    • (2008) N Engl J Med , vol.358 , pp. 2545-2559
  • 6
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapid in patients at high risk of coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapid in patients at high risk of coronary events. N Engl J Med 2007;357:2109-2122
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 7
    • 0032511601 scopus 로고    scopus 로고
    • Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39
    • UK Prospective Diabetes Study Group
    • UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713-720
    • (1998) BMJ , vol.317 , pp. 713-720
  • 8
    • 0033034404 scopus 로고    scopus 로고
    • Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP)
    • Hansson L, Lindholm LH, Niskanen L, et al. Effect of ACE inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP). Lancet 1999;353:611-616
    • (1999) Lancet , vol.353 , pp. 611-616
    • Hansson, L.1    Lindholm, L.H.2    Niskanen, L.3
  • 9
    • 0033589756 scopus 로고    scopus 로고
    • Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 (STOP- Hypertension 2) study
    • Hansson L, Lindholm LH, Ekbom T, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension 2 (STOP- Hypertension 2) study. Lancet 1999;354:1751-1756
    • (1999) Lancet , vol.354 , pp. 1751-1756
    • Hansson, L.1    Lindholm, L.H.2    Ekbom, T.3
  • 11
    • 0344373794 scopus 로고    scopus 로고
    • Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
    • The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288: 2981-2997
    • (2002) JAMA , vol.288 , pp. 2981-2997
  • 13
    • 11144355108 scopus 로고    scopus 로고
    • Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: The Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial
    • DOI 10.1291/hypres.27.181
    • Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004;27:181-191 (Pubitemid 38489080)
    • (2004) Hypertension Research , vol.27 , Issue.3 , pp. 181-191
    • Yui, Y.1    Sumiyoshi, T.2    Kodama, K.3    Hirayama, A.4    Nonogi, H.5    Kanmatsuse, K.6    Origasa, H.7    Iimura, O.8    Ishii, M.9    Saruta, T.10    Arakawa, K.11    Hosoda, S.12    Kawai, C.13
  • 15
    • 0032511580 scopus 로고    scopus 로고
    • Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38
    • UK Prospective Diabetes Study Group
    • UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
    • (1998) BMJ , vol.317 , pp. 703-713
  • 16
    • 0042835370 scopus 로고    scopus 로고
    • Diuretic versus alpha-blocker as first-step antihypertensive therapy: Final results from the Antihypertesnive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • ALLHAT Officers and Coordinators for the ALL-HAT Collaborative Research Group
    • ALLHAT Officers and Coordinators for the ALL-HAT Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertesnive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239-246
    • (2003) Hypertension , vol.42 , pp. 239-246
  • 17
    • 2942707932 scopus 로고    scopus 로고
    • Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: A report from the ALLHAT Study
    • Barzilay JI, Davis BR, Bettencourt J, et al. Cardiovascular outcomes using doxazosin vs chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT Study. J Clin Hypertens 2004;6:116-125
    • (2004) J Clin Hypertens , vol.6 , pp. 116-125
    • Barzilay, J.I.1    Davis, B.R.2    Bettencourt, J.3
  • 18
    • 22144439426 scopus 로고    scopus 로고
    • Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Whelton PK, Barzilay J, Cushman WC, et al. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:1401-1409
    • (2005) Arch Intern Med , vol.165 , pp. 1401-1409
    • Whelton, P.K.1    Barzilay, J.2    Cushman, W.C.3
  • 19
    • 20244371503 scopus 로고    scopus 로고
    • Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the ALLHAT Study
    • Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the ALLHAT Study. Arch Inten Med 2005;165:936-946
    • (2005) Arch Inten Med , vol.165 , pp. 936-946
    • Rahman, M.1    Pressel, S.2    Davis, B.R.3
  • 20
    • 15944409988 scopus 로고    scopus 로고
    • Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril
    • Wright JT, Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. JAMA 2005;293:1595-1607
    • (2005) JAMA , vol.293 , pp. 1595-1607
    • Wright, J.T.1    Dunn, J.K.2    Cutler, J.A.3
  • 21
    • 0037431734 scopus 로고    scopus 로고
    • Drug treatment for hypertension: Most patients will need a treatment cocktail - including a thiazide diuretic
    • Williams B. Drug treatment for hypertension: most patients will need a treatment cocktail - including a thiazide diuretic. BMJ 2003;326:61-62
    • (2003) BMJ , vol.326 , pp. 61-62
    • Williams, B.1
  • 22
    • 0038687520 scopus 로고    scopus 로고
    • Results of ALLHAT. Is this the final answer regarding initial anti-hypertensive drug therapy?
    • Moser M. Results of ALLHAT. Is this the final answer regarding initial anti-hypertensive drug therapy? Arch Intern Med 2003;163:1269-1273
    • (2003) Arch Intern Med , vol.163 , pp. 1269-1273
    • Moser, M.1
  • 23
    • 0037132675 scopus 로고    scopus 로고
    • The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension
    • Appel LJ. The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension. JAMA 2002;288:3039-3042
    • (2002) JAMA , vol.288 , pp. 3039-3042
    • Appel, L.J.1
  • 25
    • 20044385942 scopus 로고    scopus 로고
    • Quantitative coronary angiogram analysis: Nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study)
    • Japan Multi-center Investigation for Cardiovascular Diseases-B Study Group
    • Shinoda E, Yui Y, Kodama K, et al. Japan Multi-center Investigation for Cardiovascular Diseases-B Study Group. Quantitative coronary angiogram analysis: nifedipine retard versus angiotensin-converting enzyme inhibitors (JMIC-B side arm study). Hypertension 2005;45:1153-1158
    • (2005) Hypertension , vol.45 , pp. 1153-1158
    • Shinoda, E.1    Yui, Y.2    Kodama, K.3
  • 26
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
    • The Heart Outcomes Prevention Evaluation Study Investigators
    • The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153
    • (2000) N Engl J Med , vol.342 , pp. 145-153
  • 27
    • 0035968623 scopus 로고    scopus 로고
    • Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack
    • PROGRESS collaborative group
    • PROGRESS collaborative group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischemic attack. Lancet 2001;358:1033-1041
    • (2001) Lancet , vol.358 , pp. 1033-1041
  • 28
    • 0042330455 scopus 로고    scopus 로고
    • Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study)
    • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
    • The EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788
    • (2003) Lancet , vol.362 , pp. 782-788
  • 29
    • 7744231805 scopus 로고    scopus 로고
    • Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: A randomized controlled trial
    • Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004;292:2217-2226
    • (2004) JAMA , vol.292 , pp. 2217-2226
    • Nissen, S.E.1    Tuzcu, E.M.2    Libby, P.3
  • 30
    • 19644400972 scopus 로고    scopus 로고
    • Angiotensin-converting enzyme inhibition in stable coronary artery disease
    • The PEACE Trial Investigators
    • The PEACE Trial Investigators. Angiotensin-converting enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068
    • (2004) N Engl J Med , vol.351 , pp. 2058-2068
  • 31
    • 34247379373 scopus 로고    scopus 로고
    • Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): A randomized, open-label, blinded end-point morbidity- mortality study
    • Mochizuki S, Dahlof B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomized, open-label, blinded end-point morbidity- mortality study. Lancet 2007;369:1431-1439
    • (2007) Lancet , vol.369 , pp. 1431-1439
    • Mochizuki, S.1    Dahlof, B.2    Shimizu, M.3
  • 32
    • 17044440752 scopus 로고    scopus 로고
    • Comparative effects of ramipril on ambulatory and office blood pressures: A HOPE substudy
    • Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE substudy. Hypertension 2001;38:28-32.
    • (2001) Hypertension , vol.38 , pp. 28-32
    • Svensson, P.1    De Faire, U.2    Sleight, P.3    Yusuf, S.4    Ostergren, J.5
  • 33
    • 0027421914 scopus 로고
    • Large prospective study of ramipril in patients with hypertension
    • Kaplan NM, Sproul LE, Mulcahy WS. Large prospective study of ramipril in patients with hypertension. CARE Investigators. Clin Ther 1993;15: 810-818 (Pubitemid 23339770)
    • (1993) Clinical Therapeutics , vol.15 , Issue.5 , pp. 810-818
    • Kaplan, N.M.1    Sproul, L.E.2    Mulcahy, W.S.3
  • 34
    • 0028937111 scopus 로고
    • Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure
    • Frampton JE, Peters DH. Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure. Drugs 1995;49:440-466
    • (1995) Drugs , vol.49 , pp. 440-466
    • Frampton, J.E.1    Peters, D.H.2
  • 37
    • 6944223168 scopus 로고    scopus 로고
    • The PROGSESS trial three years later: Time for a balanced report of effectiveness
    • Wennberg R, Zimmermann C. The PROGRESS trial three years later: time for a balanced report of effectiveness. BMJ 2004;329:968-970 (Pubitemid 39422916)
    • (2004) British Medical Journal , vol.329 , Issue.7472 , pp. 968-970
    • Wennberg, R.1    Zimmermann, C.2
  • 38
    • 7044220119 scopus 로고    scopus 로고
    • Commentary: The PROGRESS trial three years later: Time for more action, less distraction
    • MacMahon S, Neal B, Rodgers A, Chalmers J. The PROGRESS trial three years later: time for more action, less distraction. BMJ 2004;329:970-971 (Pubitemid 39422917)
    • (2004) British Medical Journal , vol.329 , Issue.7472 , pp. 970-971
    • MacMahon, S.1    Neal, B.2    Rodgers, A.3    Chalmers, J.4
  • 40
    • 1542286713 scopus 로고    scopus 로고
    • LIFE: Lorsatan versus atenolol
    • Ong HT. LIFE: lorsatan versus atenolol. Lancet 2003;362:1416.
    • (2003) Lancet , vol.362 , pp. 1416
    • Ong, H.T.1
  • 41
    • 7644236592 scopus 로고    scopus 로고
    • Atenolol in hypertension: Is it a wise choice?
    • Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet 2004;364: 1684-1689
    • (2004) Lancet , vol.364 , pp. 1684-1689
    • Carlberg, B.1    Samuelsson, O.2    Lindholm, L.H.3
  • 42
    • 33744970717 scopus 로고    scopus 로고
    • Re-examining the efficacy of beta-blockers for the treatment of hypertension: A meta-analysis
    • DOI 10.1503/cmaj.060110
    • Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. CMAJ 2006;174:1737-1742 (Pubitemid 43893565)
    • (2006) Canadian Medical Association Journal , vol.174 , Issue.12 , pp. 1737-1742
    • Khan, N.1    McAlister, F.A.2
  • 43
    • 27544463207 scopus 로고    scopus 로고
    • Should beta blockers remain first choice in the treatment of primary hypertension? a meta-analysis
    • DOI 10.1016/S0140-6736(05)67573-3, PII S0140673605675733
    • Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-1553 (Pubitemid 41540112)
    • (2005) Lancet , vol.366 , Issue.9496 , pp. 1545-1553
    • Lindholm, L.H.1    Carlberg, B.2    Samuelsson, O.3
  • 46
    • 34247402881 scopus 로고    scopus 로고
    • Sum and substance in the Jikei Heart Study
    • DOI 10.1016/S0140-6736(07)60643-6, PII S0140673607606436
    • Staessen JA, Richart T. Sum and substance in the Jikei heart study. Lancet 2007;369:1407-1408 (Pubitemid 46635762)
    • (2007) Lancet , vol.369 , Issue.9571 , pp. 1407-1408
    • Staessen, J.A.1    Richart, T.2
  • 47
    • 53049109468 scopus 로고    scopus 로고
    • Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomized controlled trial
    • The Telmisartan Randomised Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND) investigators
    • The Telmisartan Randomised Assessment Study in ACE-Intolerant Subjects with Cardiovascular Disease (TRANSCEND) investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008;372:1174-1183
    • (2008) Lancet , vol.372 , pp. 1174-1183
  • 48
    • 52249116778 scopus 로고    scopus 로고
    • Telmisartan to prevent recurrent stroke and cardiovascular events
    • Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008;359:1225-1237
    • (2008) N Engl J Med , vol.359 , pp. 1225-1237
    • Yusuf, S.1    Diener, H.C.2    Sacco, R.L.3
  • 49
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril or both in patients at high risk for vascular events
    • The ONTARGET Investigators
    • The ONTARGET Investigators. Telmisartan, ramipril or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-1559
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
  • 50
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): A multicentre, randomized, double-blind, controlled trial
    • Mann JFE, Schmeider RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both in people at high vascular risk (the ONTARGET study): a multicentre, randomized, double-blind, controlled trial. Lancet 2008;372:547-553
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.E.1    Schmeider, R.E.2    McQueen, M.3
  • 51
    • 51549115092 scopus 로고    scopus 로고
    • Cardiovascular outcomes in the comparative hypertension drug trials: More consensus than controversy
    • Ong HT. Cardiovascular outcomes in the comparative hypertension drug trials: more consensus than controversy. Singapore Med J 2008;49:599-606.
    • (2008) Singapore Med J , vol.49 , pp. 599-606
    • Ong, H.T.1
  • 53
    • 0344718782 scopus 로고    scopus 로고
    • 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
    • World Health Organization, International Society of Hypertension Writing Group
    • Whitworth JA, World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003;21: 1983-1992
    • (2003) J Hypertens , vol.21 , pp. 1983-1992
    • Whitworth, J.A.1
  • 55
    • 34547615709 scopus 로고    scopus 로고
    • 2007 Guidelines for the management of arterial hypertension
    • Mancia G, de Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension. Eur Heart J 2007;28:1462-1536
    • (2007) Eur Heart J , vol.28 , pp. 1462-1536
    • Mancia, G.1    De Backer, G.2    Dominiczak, A.3
  • 56
    • 7744243662 scopus 로고    scopus 로고
    • What is the optimal blood pressure and drug therapy for patients with coronary artery disease?
    • Pepine CJ. What is the optimal blood pressure and drug therapy for patients with coronary artery disease? JAMA 2004;292:2271-2273
    • (2004) JAMA , vol.292 , pp. 2271-2273
    • Pepine, C.J.1
  • 57
    • 0037079309 scopus 로고    scopus 로고
    • Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies
    • Prospective Studies Collaboration
    • Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360: 1903-1913
    • (2002) Lancet , vol.360 , pp. 1903-1913
  • 60
    • 6944221405 scopus 로고    scopus 로고
    • Today's Agenda. We must focus on achieving favorable levels of all risk factors simultaneously
    • Daviglus ML, Liu K. Today's Agenda. We must focus on achieving favorable levels of all risk factors simultaneously. Arch Intern Med 2004;164:2086-2087
    • (2004) Arch Intern Med , vol.164 , pp. 2086-2087
    • Daviglus, M.L.1    Liu, K.2
  • 61
    • 8344222827 scopus 로고    scopus 로고
    • ACE Inhibitors for patients with vascular disease without left ventricular dysfunction-may they rest in PEACE?
    • Pitt B. ACE Inhibitors for patients with vascular disease without left ventricular dysfunction-may they rest in PEACE? N Engl J Med 2004;351: 2115-2117
    • (2004) N Engl J Med , vol.351 , pp. 2115-2117
    • Pitt, B.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.